Last reviewed · How we verify
VKA INR 2-3
At a glance
| Generic name | VKA INR 2-3 |
|---|---|
| Also known as | warfarin |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Crovalimab in People With Antiphospholipid Syndrome (APS) (PHASE2)
- Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR (PHASE3)
- Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus (PHASE3)
- Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PHASE3)
- Oral Anticoagulation in Haemodialysis Patients (PHASE4)
- Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation (PHASE4)
- DOAC Versus VKA After Cardiac Surgery (PHASE2)
- Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VKA INR 2-3 CI brief — competitive landscape report
- VKA INR 2-3 updates RSS · CI watch RSS
- AstraZeneca portfolio CI